Navigation Links
Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
Date:1/8/2008

ctor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe. BioMarin and Merck Serono estimate that Kuvan could be a potential treatment option for approximately 30 percent to 50 percent of the estimated 50,000 identified PKU patients in the developed world.

Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Kuvan has received seven years of market exclusivity in the United States. In November 2007, Merck Serono submitted a Marketing Authorization Application (MAA) to the EMEA for sapropterin dihydrochloride as an oral treatment for patients suffering from HPA due to PKU or BH4 deficiency. If approved in the EU, it will receive 10 years of market exclusivity for this indication.

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. To learn more about PKU, please visit http://www.PKU.com.

About Fairview Specialty Pharmacy

Fairview Specialty Pharmacy provides personal medication management services to patients who take high-cost or self-injected drugs for chronic conditions. Fairview Specialty Pharmacy ensures that patients receive their medications safely and on time via services including medication management and monitoring, free shipping anywhere in the US, and monthly refill reminder phone calls. All calls are answered by "live" pha
'/>"/>

SOURCE Fairview Specialty Pharmacy
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Specialty Blades, Inc. Completes Acquisition of Popper and Sons, Inc.
2. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
3. Heska to Present at New York Society of Security Analysts Biotech/Specialty Pharma Conference
4. Albemarle Raises Prices of Specialty Aluminas
5. Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise
6. Specialty Underwriters Alliance to Present at 2007 FBR Capital Markets Investor Conference
7. Survey shows gender differences are factor when surgeons in training choose a subspecialty
8. Packard Childrens Hospital Opens New South Bay Specialty Clinic Bringing Specialty Care Close to Home
9. Consumer Specialty Products Association Responds to European Study Investigating Spray Products and Asthma
10. Mylan Announces Management of Specialty Business, Dey L.P.
11. Consumer Specialty Products Association Highly Critical of NRDC Study on Home Air Fresheners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... turns 160 years of neuroanatomy on its head. , ... essential for the fast transmission of impulses along the ... thought, according to a new work lead by Professor ... and the University,s Department of Stem Cell and Regenerative ... Department of Molecular and Cellular Biology. , "Myelin is ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2
... pink race gear on e Bay in favor of Susan ... Awareness month and pink is// the symbolic color of Breast ... Racing to create exclusive warriors in pink livery with exclusive ... the eBay auction. ,Parts of the Warrior in ...
... a team of researchers from the Edinburgh University, the risk ... a variant of a gene called// neuregulin. ,This ... high risk of developing schizophrenia were monitored for 10 years ... the volunteers had 2 or more relatives affected by this ...
... packets of counterfeit condoms of Durex best-selling 'extra safe' range ... ,A Durex spokeswoman stated that the company could not 'guarantee ... that were on sale in UK was also unknown,These counterfeits ... When tests were conducted at the company's laboratories it was ...
... which could protect children from meningococcal disease is being ... disease has not been// available. ,The researchers, ... Child Health Research and Princess Margaret Hospital for Children, ... meningococcal B strain which is the most common. It is ...
... Monday called for fast tracking of the approval ... effective against extremely drug resistant// tuberculosis(XDR-TB) which is ... ,MSF otherwise called Doctors Without Borders(DWB) has ... Food and Drug Administraton(USFDA) and European Medicines Agency ...
... must have spice in every Indian home now finds itself ... uses to fight// many tubborn inflammations and degenerative disorders thus ... scripts of Ayurveda. ,According to a recent study ... Janet L. Funk, MD, working with Barbara N. Timmermann, PhD ...
Cached Medicine News:Health News:Gene Variant associated with Schizophrenia identified 2Health News:Faster Approval Procedures Urged For New TB Drugs 2
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... found, results showed CYPHER(R) Stent ... had lower mortality and heart attack rates, ... patient data from a two-year randomized controlled trial comparing,the ... no,statistically significant differences in safety outcomes between the two,drug- ...
... Clinical investigators at the,European Society of Cardiology Congress ... Coronary Stent continued to,provide clinical benefits compared to a ... years of follow-up with no differences in safety. ... arm of the,study continued to be significantly less likely ...
Cached Medicine Technology:Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent 2Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent 3Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 3Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 5
... product line has the right product for ... and from intubated patients to patients with ... both anesthesia and critical care applications., ... protection for patients and staff members. This ...
Passive heat and moisture exchangers for respiratory applications....
Passive heat and moisture exchangers for respiratory applications....
Ballard trach care HMES and filters, tv 500, HME...
Medicine Products: